Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia

• Status: Completed
• Trial end date: 2020-02-13
• Target enrollment: 0
• Participant gender: All

Summary

Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations. Thus, in this study, we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Pitavastatin

Criteria

Inclusion Criteria:

• Age 20-80 years

• Patients with intermediate or low cardiovascular risks needing the statin treatment

• Patients with intermediate or low cardiovascular risks treating the statin treatment

Exclusion Criteria:

• Patients without signed informed consent

• Patients with myopathy

• Pregnant women or women with potential childbearing

• Patients with diabetes

• Patients with established coronary artery disease

• Patients with heart failure

• Life expectancy less than 1 year